drugset / Trial / NCT02003118

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

NCT02003118 ↗

Phase 2 Completed 266 enrolled Akron Molecules AG
RandomizedParallel-groupTriple-blindTreatment

Summary

This proof of concept study will be a placebo controlled, randomised, double blind, parallel study. The purpose of the study is to determine efficacy for AKR 202 in the treatment of osteoarthritis (OA) pain in the knee.

Timeline

Start
2013-10
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AKR 202 Unknown — —

Indications